Publications by authors named "Ana Groh"
Article Synopsis
- The study investigates the serum levels of isoniazid and rifampicin in drug-sensitive TB patients treated between 2019 and 2023, focusing on sex-specific differences in drug levels.
- The research found that while there were no significant differences in isoniazid levels between sexes, female patients had higher rifampicin levels compared to male patients despite similar weight-adjusted dosing.
- Adverse effects were more prevalent in women during treatment, highlighting the need for clinicians to consider sex differences in therapeutic drug monitoring (TDM) for TB treatment.*
Background: With integrase strand transfer inhibitor (INSTI) use associated with increased body mass index (BMI) and BMI increases associated with higher diabetes mellitus (DM) risk, this study explored the relationship between INSTI/non-INSTI regimens, BMI changes, and DM risk.
Methods: RESPOND participants were included if they had CD4, HIV RNA, and ≥ 2 BMI measurements during follow up. Those with prior DM were excluded.
Article Synopsis
- SARS-CoV-2 is the virus responsible for COVID-19, and accurate diagnostic testing is crucial to manage its spread and treatment effectively.
- A study was conducted on 30 households to analyze the progression of viral markers (RNA and antigen) soon after infection, noting that viral RNA was found in saliva earlier than in nasal swabs for some individuals.
- Results showed RNA detection was more sensitive, while antigen detection correlated better with contagiousness, helping to refine the interpretation of SARS-CoV-2 test results for better patient care.
Article Synopsis
- The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
- Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
- Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.
Incidence of anal carcinoma (AC) in people living with HIV (PLWH) is increased compared to the general population. Adverse effects of chemoradiotherapy (CRT) on the immune system are associated with a significant detrimental prognosis on overall survival in patients receiving CRT for solid tumors. The aim of this study was to evaluate immunological factors, in particular the differences in recovery of CD4 and CD8 cell counts before and after CRT for AC in PLWH.
View Article and Find Full Text PDFArticle Synopsis
- * 326 patients were analyzed, showing that COVID-19 severity ranged from mild to critical, with 21% of patients experiencing mild cases and an overall mortality rate of 21%.
- * Key risk factors for higher mortality included being over 50 years old, having multiple comorbidities, active hematologic disease, and experiencing COVID-19 within a year of transplantation.
Article Synopsis
- The study examined the impact of government-funded pre-exposure prophylaxis (PrEP) on sexually transmitted infections (STIs) among people living with HIV, specifically in men who have sex with men, after PrEP became covered by German health insurance in September 2019.
- Researchers enrolled 143 patients diagnosed with STIs over two groups: one year before and one year after PrEP coverage, noting an increase in STIs, particularly syphilis and chlamydia, in the latter group.
- The findings suggest a trend of rising STI rates among people living with HIV following the introduction of PrEP coverage, highlighting the need for increased discussions about STI risks between these overlapping communities.
Genetic Predisposition and the Variable Course of Infectious Diseases.
Dtsch Arztebl Int
February 2022
Background: Contact with a pathogen is followed by variable courses of infectious disease, which are only partly explicable by classical risk factors. The susceptibility to infection is variable, as is the course of disease after infection. In this review, we discuss the extent to which this variation is due to genetic factors of the affected individual (the host).
View Article and Find Full Text PDF